Geode Capital Management LLC Has $3.81 Million Stock Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Geode Capital Management LLC boosted its stake in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 16.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 303,647 shares of the company’s stock after purchasing an additional 43,840 shares during the quarter. Geode Capital Management LLC owned about 0.33% of Gyre Therapeutics worth $3,808,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GYRE. FMR LLC bought a new position in Gyre Therapeutics in the 3rd quarter valued at about $47,000. Barclays PLC increased its stake in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the last quarter. Rhumbline Advisers acquired a new position in Gyre Therapeutics during the second quarter valued at approximately $123,000. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics during the second quarter worth $166,000. Finally, Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics during the second quarter worth $218,000. Institutional investors own 23.99% of the company’s stock.

Insider Buying and Selling at Gyre Therapeutics

In other news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 12,000 shares of company stock worth $143,480 over the last 90 days. Insiders own 19.52% of the company’s stock.

Gyre Therapeutics Trading Down 9.8 %

Shares of GYRE opened at $9.73 on Tuesday. Gyre Therapeutics, Inc. has a 52-week low of $8.26 and a 52-week high of $27.10. The business’s fifty day moving average is $12.40 and its 200-day moving average is $12.68.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.